Replies to post #114845 on Biotech Values

[DewDiligence]

Barron’s compliments itself on its great MNTA call from Feb 2011 (LOL):

http://online.barrons.com/article/SB50001424052748704284404577157213125724728.html

Generic-drug maker Momenta Pharmaceuticals (MNTA) jumped more than 31% after we published our story in February, compared to a 9% decline by the relevant benchmark.

In truth, Barron’s Feb 2011 article on MNTA was moronic (as noted in #msg-59968048).